Skip to main content

Table 4 Lipids, statins and anti-platelet therapy

From: Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study

Characteristics Total
(n = 1129)
CKD Stage 3 CKD Stage 4 Pvalue
Total cholesterol (mg/dL; mean ± SD [range]) 195 ± 42 [30-171] 193 ± 38 [93-313] 196 ± 43 [74-396] 0.27
LDL-cholesterol (mg/dL; mean ± SD [range]) 116 ± 37 [30-271] 116 ± 38 [39-217] 116 ± 36 [30-271] 0.94
HDL-cholesterol (mg/dL; mean ± SD [range]) 50 ± 14 [2-99] 49 ± 13 [20-99] 51 ± 14 [23-99] 0.15
Triglycerides (mg/dL; mean ± SD [range]) 147 ± 89 [40-900] 151 ± 92 [40-900] 143 ± 87 [40-860] 0.14
Patients treated with statins for cholesterol control (%) 54.7 56.2 53.2 0.30
Patients with LDL-c < 100 mg/dl (%) 34.8 32.9 36.0 0.32
Patients with LDL-c < 70 mg/dl (%) 8.3 7.6 8.8 0.52
Patients treated with aspirin or other anti-platelet agents (%) 46.2 45.3 47.11 0.52
Patients with serum albumin in normal range (%) 87.9 89.0 88.6 0.54
Serum albumin (g/dL) [range] 3.9 ± 0.4 [1.7-6] 3.9 ± 0.4 [1.7-6] 3.9 ± 0.4 [1.7-6] 0.79